Parkinson's Disease: Newcastle-under-Lyme
The question
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of procuring Produodopa via the NHS on the treatment of Parkinson's disease in Newcastle-Under Lyme constituency.
Answered by Karin Smyth
The National Institute for Health and Care Excellence (NICE) published guidance recommending foslevodopa–foscarbidopa (Produodopa) for patients with Parkinson’s disease meeting specified clinical criteria, in November 2023. Produodopa is now available to eligible National Health Service patients in England, including in Newcastle-Under Lyme, in line with the NICE’s recommendations.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →